B细胞靶向治疗SLE相关温抗体型自身免疫性溶血性贫血的真实世界队列研究
该多中心回顾性队列研究比较了B细胞靶向治疗与常规糖皮质激素免疫抑制治疗在初发SLE相关温抗体型AIHA中的疗效。纳入70例患者,B细胞靶向治疗组43例,常规治疗组27例。结果显示6个月总缓解率两组无显著差异(89.7% vs 85.7%,OR 1.45,95%CI 0.19-9.61,P=0.687),但B细胞靶向治疗组完全缓解率数值更高、1个月泼尼松等效剂量更低。
要点
- B细胞靶向治疗与常规治疗6个月总缓解率无显著差异。
- B细胞靶向治疗组完全缓解率数值更高(61.5% vs 42.9%)。
- B细胞靶向治疗组1个月泼尼松等效剂量更低(40.0 vs 50.0 mg/day,P=0.023)。
核心结论
- B细胞靶向治疗与常规糖皮质激素免疫抑制治疗在6个月和12个月总缓解率上无显著差异。
- B细胞靶向治疗组完全缓解率数值更高、12个月缓解更稳定且激素减量更早,但属探索性发现,需前瞻性验证。
研究设计与样本
- 多中心回顾性队列研究,纳入2020年3月1日至2026年2月1日期间SLE相关温抗体型AIHA患者。
- 纳入标准为基线血红蛋白<90 g/l且有溶血实验室证据;共筛查246例SLE住院记录,最终纳入70例。
- 27例接受常规治疗,43例接受B细胞靶向治疗(利妥昔单抗、贝利尤单抗或泰它西普),治疗暴露在起始14天内分类。
主要发现
- 6个月总缓解率:B细胞靶向治疗组89.7%,常规治疗组85.7%(OR 1.45;95%CI 0.19-9.61;P=0.687)。
- 完全缓解率:B细胞靶向治疗组61.5%,常规治疗组42.9%。
- 1个月泼尼松等效剂量:B细胞靶向治疗组40.0 mg/day,常规治疗组50.0 mg/day(P=0.023)。
- 12个月总缓解率:B细胞靶向治疗组89.3%,常规治疗组73.7%,无复发生存无显著差异。
- 6个月内记录13例住院不良事件(包括致死事件);泰它西普治疗患者(n=7)中所有可评估者在1、3、6个月均达总缓解。
关键数值与推荐
- 基线血红蛋白<90 g/l且有溶血实验室证据为纳入标准。
- 主要结局为6个月总缓解率(完全或部分缓解)。
- B细胞靶向治疗组较年轻且基线SLEDAI-2K评分更高。
临床怎么用
- 对于初发SLE相关温抗体型AIHA,B细胞靶向治疗在6个月总缓解率上与常规治疗相当,但完全缓解率数值更高且激素减量更早。
- 泰它西普在少数患者中显示所有可评估者达总缓解,但样本量小,需进一步验证。
局限性
- 回顾性队列设计,样本量较小(70例),B细胞靶向治疗组与常规治疗组基线特征不平衡(年龄和SLEDAI-2K评分差异)。
- 泰它西普亚组样本量仅7例,结果属探索性。
- 6个月内记录13例住院不良事件包括致死事件,但未详细说明组间分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare B cell-targeted therapy with conventional glucocorticoid-based immunosuppression in first-episode systemic lupus erythematosus (SLE)-associated warm autoimmune haemolytic anaemia (AIHA). METHODS: We conducted a multicampus retrospective cohort study from 1 March 2020 to 1 February 2026. Eligible patients had SLE-associated warm AIHA, baseline haemoglobin <90 g/l and laboratory evidence of haemolysis. Treatment exposure was classified within 14 days of treatment initiation: conventional therapy or B cell-targeted therapy with rituximab, belimumab or telitacicept. The primary outcome was 6-month overall response rate (ORR; complete or partial response). RESULTS: Of 246 SLE hospitalization records screened, 70 patients were included; 27 received conventional therapy and 43 received B cell-targeted therapy. The B cell-targeted therapy group was younger and had higher baseline SLEDAI-2K scores. Six-month ORR was 89.7% with B cell-targeted therapy and 85.7% with conventional therapy (odds ratio [OR] 1.45; 95% CI: 0.19, 9.61; P = 0.687), with corresponding complete response rates of 61.5% and 42.9%. At 1 month, prednisone-equivalent dose was lower with B cell-targeted therapy (40.0 vs 50.0 mg/day; P = 0.023). Twelve-month ORR was 89.3% with B cell-targeted therapy and 73.7% with conventional therapy, and relapse-free survival did not differ significantly. Within 6 months, 13 inpatient-recorded adverse-event episodes, including fatal events, were documented. In telitacicept-treated patients (n = 7), all evaluable patients achieved ORR at 1, 3 and 6 months. CONCLUSION: Six- and 12-month ORR did not differ significantly between treatment strategies. The numerically higher complete response rate, more stable 12-month response and earlier glucocorticoid reduction with B cell-targeted therapy, together with the telitacicept findings, are exploratory and require prospective validation.
引用
- Sun Y, Wang Y, Cao H, et al. B-cell-targeted therapy for systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia: a real-world comparative cohort study. Rheumatology (Oxford). 2026. PMID: 42786640. doi:10.1093/rheumatology/keag535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。